Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The role of immunotherapy in the AML treatment landscape

Thomas Cluzeau • 12 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Antibodies Azacitidine CAR-T Magrolimab Venetoclax
ENHANCE-2

In this video, Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, shares some insights into the role of immunotherapy in the treatment of acute myeloid leukemia (AML). Dr Cluzeau first comments on the importance of allogeneic stem cell transplantation (alloSCT) in AML, and then goes on to discuss the promise of novel immunotherapies, including CAR-T cells and antibodies. To conclude, Dr Cluzeau draws focus on the potential of magrolimab for the treatment of this disease and future outlooks. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Thomas Cluzeau

1:40
Highlights in LR-MDS at the ASH 2023 meeting
Thomas Cluzeau • 9 Dec 2023
1:55
Long-term real-world experience of CPX-351 in patients with t-AML and MRC-AML
Thomas Cluzeau • 9 Dec 2023
2:17
VENTOGRAFT trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following alloSCT
Thomas Cluzeau • 10 Dec 2023
Novel targets, combinations & treatments
Eunice Wang et al. • 4 Sep 2023

Related Videos

3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Cytogenetic and molecular associations with outcomes in HR-MDS treated with HMAs plus venetoclax
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals